Congress delivered a significant Christmas present to President Trump last month and to industry by enacting landmark tax reform legislation that makes major changes in the corporate tax structure. The result may be billions in savings for multi-national biopharma companies. In addition to lOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.